🌏 Trade diplomacy is shifting again. The US and China are reopening commercial channels, pharmaceutical firms face a potential 100% tariff shock, and new trade corridors are emerging between the UK and the Gulf.
Welcome to This Week in Trade #10, your quick, curated briefing on the global trade developments shaping markets, supply chains, and international economic policy.
This week, we unpack the Trump–Xi summit in Beijing, new US Section 232 pharmaceutical tariffs, and the latest trade and regulatory developments across Europe and the Middle East.
📌 This week’s key stories:
• Trump–Xi summit signals partial US–China commercial thaw
• Proposed US–China Board of Trade and investment coordination
• Taiwan tensions remain unresolved despite economic engagement
• US Section 232 pharmaceutical tariffs could reach 100%
• Onshoring and pricing agreements may reduce tariff exposure
• EU launches CBAM rebate consultation for third-country carbon pricing
• UK–GCC free trade agreement nears completion
• Austria proposes €2 delivery tax on distance sales packages
💡 Key takeaway:
Governments are increasingly blending trade policy, industrial strategy, and national security tools — creating both new commercial openings and major compliance risks for globally exposed businesses.
⏱️ Timestamps:
00:00 Trade Shock Opener
00:46 US China Summit Deals
01:30 Boards Trade Investment
02:04 Taiwan Risk Reality
02:37 Pharma Tariff Bomb
03:00 Onshoring Escape Hatch
03:44 Compliance And Penalties
04:10 CBAM Rebate Rules
04:50 UK GCC FTA Nears
05:14 Austria Delivery Tax
05:35 Wrap Up And Feedback
🤝 This briefcast builds on the weekly trade insights curated by George Riddell
🔗 Follow George on LinkedIn:
LinkedIn Profile
🌐 Explore more from the Geneva Trade Platform:
Geneva Trade Platform
🔗 Follow the Geneva Trade Platform on LinkedIn:
LinkedIn Page
📩 Have feedback or topics you’d like us to cover? Let us know in the comments.
🔔 Subscribe for weekly updates on global trade, WTO developments, supply chains, and international economic policy.